24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Sputum or blood eosinophil association with clinical measures of COPD severity in the SPIROMICS cohort

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Eosinophils in blood and sputum in chronic obstructive pulmonary disease (COPD) have been associated with more frequent exacerbations, lower lung function, and corticosteroid responsiveness. We hypothesized increased eosinophils are associated with a severe COPD phenotype, including exacerbation frequency, and tested whether blood eosinophils reliably predict sputum eosinophils.

          Methods

          Comprehensive baseline data on SPIROMICS subjects, recruited for a range of COPD severity for smokers with ≥20 pack year history, included demographics, questionnaires, clinical assessments, quantitative computed tomography (QCT), blood and induced sputum.

          Findings

          Significantly, stratification by mean sputum eosinophils ≥1·25% (N=827) was associated with reduced FEV 1 % predicted (differences: 10% pre-bronchodilator, 4·7% post-bronchodilator), QCT density measures for emphysema and air trapping, and exacerbations treated with corticosteroids (p=0·002). In contrast, stratification by mean blood eosinophils ≥200/µL (N=2499) showed that FEV 1 % predicted was significant between low and high blood subgroups, but less than observed between sputum subgroups (blood eosinophil group differences: 4·2% pre-bronchodilator, 2·7% post-bronchodilator), slightly increased airway wall thickness (0·02 mm, p=0·032), greater symptoms (p=0·037), and wheezing (p=0·018), but no evidence of association with COPD exacerbations or other indices of severity. Blood eosinophils showed weak although significant association with sputum eosinophils (ROC AUC=0·64, p<0·001), but with a high false discovery rate (72%). Elevated sputum eosinophils, with or without blood eosinophils, were associated with lower lung function. Elevated blood eosinophils only in combination with elevated sputum eosinophils were associated with COPD exacerbations.

          Interpretation

          Stratification of SPIROMICS subjects by blood eosinophils alone showed minimal clinical differences and no association with exacerbations, whereas stratification by sputum eosinophils was associated with larger phenotypic differences and COPD exacerbations. Importantly, increased blood eosinophils did not reliably predict airway eosinophils in induced sputum.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Susceptibility to exacerbation in chronic obstructive pulmonary disease.

          Although we know that exacerbations are key events in chronic obstructive pulmonary disease (COPD), our understanding of their frequency, determinants, and effects is incomplete. In a large observational cohort, we tested the hypothesis that there is a frequent-exacerbation phenotype of COPD that is independent of disease severity. We analyzed the frequency and associations of exacerbation in 2138 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Exacerbations were defined as events that led a care provider to prescribe antibiotics or corticosteroids (or both) or that led to hospitalization (severe exacerbations). Exacerbation frequency was observed over a period of 3 years. Exacerbations became more frequent (and more severe) as the severity of COPD increased; exacerbation rates in the first year of follow-up were 0.85 per person for patients with stage 2 COPD (with stage defined in accordance with Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage 3, and 2.00 for patients with stage 4. Overall, 22% of patients with stage 2 disease, 33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more in the first year of follow-up). The single best predictor of exacerbations, across all GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype appeared to be relatively stable over a period of 3 years and could be predicted on the basis of the patient's recall of previous treated events. In addition to its association with more severe disease and prior exacerbations, the phenotype was independently associated with a history of gastroesophageal reflux or heartburn, poorer quality of life, and elevated white-cell count. Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype. This has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT00292552.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.

            Currently, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) of less than 0.70 as assessed by spirometry after bronchodilator use. However, many smokers who do not meet this definition have respiratory symptoms.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial

              Blood eosinophil counts might predict response to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. We used data from the WISDOM trial to assess whether patients with COPD with higher blood eosinophil counts would be more likely to have exacerbations if ICS treatment was withdrawn.
                Bookmark

                Author and article information

                Journal
                101605555
                41464
                Lancet Respir Med
                Lancet Respir Med
                The Lancet. Respiratory medicine
                2213-2600
                2213-2619
                27 January 2018
                13 November 2017
                December 2017
                01 December 2018
                : 5
                : 12
                : 956-967
                Affiliations
                [1 ]Wake Forest School of Medicine, Winston-Salem, NC
                [2 ]Weill Cornell Medical College of Cornell University, New York, NY
                [3 ]VA Ann Arbor Healthcare System
                [4 ]University of Michigan, Ann Arbor, MI
                [5 ]University of North Carolina School of Medicine, Chapel Hill, NC
                [6 ]Johns Hopkins University, Baltimore, MD
                [7 ]University of California, San Francisco, CA
                [8 ]University of Arizona College of Medicine, Tucson, AZ
                [9 ]Columbia University/Presbyterian Hospital, New York, NY
                [10 ]University of North Carolina at Chapel Hill, Chapel Hill, NC
                [11 ]David Geffen School of Medicine, Los Angeles, CA
                [12 ]University of Iowa, Iowa City, IA
                [13 ]University of Utah Health Sciences Center, Salt Lake City, UT
                [14 ]Department of Veterans Affairs Medical Center, Salt Lake City, Utah
                Author notes
                Corresponding author: Annette T. Hastie, ahastie@ 123456wakehealth.edu , Center for Genomics and Personalized Medicine Research, One Medical Center Blvd, NRC-G70, Wake Forest School of Medicine, Winston-Salem, NC 27157, Phone: (336) 713-7522, Fax: (336) 713-7544
                Article
                NIHMS922126
                10.1016/S2213-2600(17)30432-0
                5849066
                29146301
                d3351f05-5df9-4e4e-87a3-8de452eb8d9a

                This manuscript version is made available under the CC BY-NC-ND 4.0 license.

                History
                Categories
                Article

                copd severity,airway eosinophilia,emphysema,hyperinflation,air-trapping

                Comments

                Comment on this article